We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
Fusco V., Campisi G., Bedogni A. (2020). Adjuvant denosumab in early breast-cancer. THE LANCET ONCOLOGY, 21(3), e124-e124 [10.1016/S1470-2045(20)30066-8].
Adjuvant denosumab in early breast-cancer
Fusco V.
;Campisi G.;Bedogni A.
2020-01-01
Abstract
We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS1470204520300668.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
32.97 kB
Formato
Adobe PDF
|
32.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
